BINDING OF PERMIXON, A NEW TREATMENT FOR PROSTATIC BENIGN HYPERPLASIA, TO THE CYTOSOLIC ANDROGEN RECEPTOR IN THE RAT PROSTATE

被引：65
|
作者：
CARILLA, E [1 ]
BRILEY, M [1 ]
FAURAN, F [1 ]
SULTAN, C [1 ]
DUVILLIERS, C [1 ]
机构：
[1] INSERM,U58,F-34100 MONTPELLIER,FRANCE
来源：
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 1984年 / 20卷 / 01期
关键词：
D O I：
10.1016/0022-4731(84)90265-6
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：521 / 523
页数：3
相关论文
共 50 条
  • [31] Permixon(R) - An overview of its pharmacological activities as regards medical treatment of benign prostatic hyperplasia (BPH)
    Raynaud, JP
    BPH FROM MOLECULAR BIOLOGY TO PATIENT RELIEF, 1996, : 57 - 69
  • [32] Real-World Use of Permixon® in Benign Prostatic Hyperplasia - Determining Appropriate Monotherapy and Combination Treatment
    Perry, Richard
    Milligan, Gary
    Anderson, Peter
    Gillon, Andrew
    White, Maren
    ADVANCES IN THERAPY, 2012, 29 (06) : 538 - 550
  • [33] The androgen receptor CAG repeat length polymorphism associates with prostate volume in Finnish men with benign prostatic hyperplasia
    Renko, Outi
    Savolainen, Eeva-Riitta
    Loikkanen, Ildiko
    Paavonen, Timo K.
    Vaarala, Markku H.
    DNA AND CELL BIOLOGY, 2008, 27 (02) : 109 - 113
  • [34] FAT BOOSTS, WHILE ANDROGEN RECEPTOR ACTIVATION COUNTERACTS, BENIGN PROSTATIC HYPERPLASIA-ASSOCIATED PROSTATE INFLAMMATION
    Vignozzi, L.
    Gacci, M.
    Cellai, I
    Santi, R.
    Corona, G.
    Morelli, A.
    Rastrelli, G.
    Comeglio, P.
    De Nunzio, C.
    Carini, M.
    Maggi, M.
    JOURNAL OF SEXUAL MEDICINE, 2012, 9 : 323 - 323
  • [35] Androgen receptor GGC polymorphism and testosterone levels associated with high risk of prostate cancer and benign prostatic hyperplasia
    Vanderlei Biolchi
    Brasil Silva Neto
    Diego Bromfman Pianta
    Walter José Koff
    Milton Berger
    Ilma Simoni Brum
    Molecular Biology Reports, 2013, 40 : 2749 - 2756
  • [36] Androgen receptor GGC polymorphism and testosterone levels associated with high risk of prostate cancer and benign prostatic hyperplasia
    Biolchi, Vanderlei
    Neto, Brasil Silva
    Pianta, Diego Bromfman
    Koff, Walter Jose
    Berger, Milton
    Brum, Ilma Simoni
    MOLECULAR BIOLOGY REPORTS, 2013, 40 (03) : 2749 - 2756
  • [37] Real-World Use of Permixon® in Benign Prostatic Hyperplasia — Determining Appropriate Monotherapy and Combination Treatment
    Richard Perry
    Gary Milligan
    Peter Anderson
    Andrew Gillon
    Maren White
    Advances in Therapy, 2012, 29 : 538 - 550
  • [38] Hexanic Extract of Serenoa repens (Permixon®): A Review in Symptomatic Benign Prostatic Hyperplasia
    Hannah A. Blair
    Drugs & Aging, 2022, 39 : 235 - 243
  • [39] Benign prostatic hyperplasia, prostate cancer
    Lebdai, S.
    PROGRES EN UROLOGIE, 2017, 27 (03): : F60 - F62
  • [40] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2015, 25 : F82 - F84
12345